Castle Biosciences, Inc. (CSTL) Balance Sheet

The increase in total assets is driven primarily by a surge in property, plant, and equipment, which nearly tripled from $44.9M to $118.9M over the period, reflecting heavy investment in lab capacity. Equity has grown consistently, supported by capital raises and modest retained earnings improvements, suggesting the company is funding growth without excessive leverage. However, the persistent negative retained earnings, which stood at -$240.9M in Q2 2026, indicate that accumulated losses continue to weigh on the equity base, though the trend is improving as losses narrow.

The debt level is modest relative to equity and assets, and the current ratio of 6.04 suggests strong short-term solvency. The stability of debt over the past year, despite significant capital expenditures, implies that the company is funding its expansion through cash reserves and equity rather than debt. This conservative leverage provides financial flexibility, but investors should monitor whether the company will need to increase debt as cash burn continues, especially if reimbursement uncertainties materialize.

The rapid growth in PP&E suggests significant investment in laboratory automation and capacity to support the expanding test portfolio. Goodwill is minimal, reducing the risk of impairment charges, and the asset mix is becoming more tangible, which may improve operational efficiency but also increases fixed costs. The increase in PP&E aligns with the company's capital expenditure pattern, which averaged 10.4% of revenue, indicating a deliberate strategy to build scale.

The growth in equity is primarily attributable to external financing rather than organic earnings, as evidenced by the persistent negative retained earnings. This suggests that the company is reliant on investor capital to fund operations and growth, which may dilute existing shareholders over time. However, the lack of share repurchases and dividends indicates a reinvestment strategy, and the recent narrowing of losses suggests that the company may be approaching a point where it can generate positive retained earnings.

The decline in cash is notable, but the company still holds a substantial buffer to fund operations and capital expenditures. The current ratio, though lower than the 9.37 seen in Q1 2025, remains well above 1, suggesting that the company can meet its near-term liabilities comfortably. Given the negative operating margins and ongoing cash burn, the cash runway is a key metric to monitor, but the current liquidity position appears adequate to support the company through the next several quarters.